Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Dasatinib
Related studies linked through entity extraction aliases.
Dasatinib and Crizotinib in Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
- Status
- COMPLETED
- Phase
- PHASE2
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
- Status
- COMPLETED
- Phase
- PHASE4
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
- Status
- COMPLETED
- Phase
- PHASE1
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
- Status
- COMPLETED
- Phase
- PHASE1
Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
- Status
- COMPLETED
- Phase
- NA
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
- Status
- UNKNOWN
- Phase
- PHASE2
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
- Status
- COMPLETED
- Phase
- PHASE2
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
- Status
- TERMINATED
- Phase
- PHASE2
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Dasatinib in Advanced Squamous Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1